AbCellera Biologics Inc
Company Profile
Business description
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
Contact
150 W 4th Avenue
VancouverBCV5Y 1G6
CANT: +1 604 559-9005
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
562
Stocks News & Analysis
stocks
Ask the analyst: Where does GYG stand following its US exit?
stocks
Chart of the Week: The long term headwinds facing copper shares
stocks
Australia’s oldest REIT undervalued
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,922.40 | 0.70 | 0.01% |
| CAC 40 | 8,337.29 | 66.70 | -0.79% |
| DAX 40 | 25,040.28 | 44.47 | 0.18% |
| Dow JONES (US) | 52,305.24 | 13.96 | -0.03% |
| FTSE 100 | 10,478.34 | 18.78 | -0.18% |
| HKSE | 23,154.41 | 273.39 | 1.19% |
| NASDAQ | 26,040.03 | 173.69 | -0.66% |
| Nikkei 225 | 69,264.46 | 1,210.50 | -1.72% |
| NZX 50 Index | 13,525.52 | 84.98 | -0.62% |
| S&P 500 | 7,483.23 | 16.13 | -0.22% |
| S&P/ASX 200 | 8,718.30 | 7.70 | 0.09% |
| SSE Composite Index | 4,075.31 | 37.13 | -0.90% |